Kobe-Based M's Science To Accelerate Cerebral Infarction Clinical Drug Trials
This article was originally published in PharmAsia News
Executive Summary
Kobe-based clinical stage drug discovery and development venture company, M's Science, announced the allocation of new shares to a third party May 26 in an effort to speed up clinical trials for SA4503. Developed by the company, SA4503 is a drug agent with potential applications for treating cerebral infarction and depression, and currently it is in Phase II trials in Europe. The ¥940 million investment infusion comes from 16 venture capital companies, including Japan Asia Investment Corp, Yasuda Enterprise Development and First Track Initiative. The funds will be used to speed up the trials. (Click here for more - Japanese language